Search
Innovation List
PDIA1 and PDIA3 inhibitors for the therapy of i.a. thrombosis and tumor metastasis
Industry: Pharmaceutical industry
Manager: Prof. dr hab. Stefan Chłopicki
Broker: dr Maciej Łojewski
Phone: 691 414 007
Email: maciej.lojewski@uj.edu.pl
Possible forms of commercialization: sale, licence
These compounds show therapeutic activity and are not cytotoxic. In particular, they can be used to treat and prevent excessive platelet activation and thrombosis. The influence of PDI A1 and A3 inhibitors on the transepithelial migration of neoplastic cells (metastasis) was also investigated. In order to "nest" in a new place, neoplastic cells must pass through the endothelium. PDI is essential in this process. PDIA1 inhibitors inhibit the activation of integrins, which prevents the tumor cell from migrating through the endothelium.
Keywords: PDI inhibitors, endothelium, anticoagulation, anti-metastasis, aromatic sulfonamide derivatives
